Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis

Area of Science:

• Rheumatology
• Vascular Medicine
• Pharmacology

Background:

• Systemic sclerosis (SS) frequently causes severe Raynaud's phenomenon (RP).
• Vascular insufficiency is a hallmark complication of SS, impacting patient quality of life.
• Limited effective treatments exist for RP associated with connective tissue diseases.

Purpose of the Study:

• To evaluate the efficacy and safety of prostaglandin E1 (PGE1) in patients with SS and severe RP.
• To assess PGE1's impact on cold tolerance, RP attack frequency and severity, and ischemic ulcer healing.
• To investigate PGE1's effects on pain, hand function, and peripheral temperature.

Main Methods:

• A single-blind, cross-over study involving twelve SS patients with severe RP.
• Patients received 72-hour intravenous infusions of PGE1 (6-10 ng/kg/min) or saline/dextrose.
• Measurements included cold tolerance, RP attack frequency/severity, pain (visual analogue scale), hand function, and thermography.

Main Results:

• PGE1 infusions improved subjective cold tolerance and reduced Raynaud's phenomenon attack frequency, severity, and duration.
• Significant pain reduction (P < 0.05) and increased finger/hand temperature (P < 0.001) were observed with PGE1.
• Two patients experienced healing of ischemic ulcers; no significant change in objective hand function was noted.

Conclusions:

• Prostaglandin E1 is a well-tolerated treatment option for Raynaud's phenomenon in systemic sclerosis.
• PGE1 demonstrates potential benefits for vascular insufficiency associated with SS and other connective tissue diseases.
• Further research is warranted to confirm PGE1's long-term efficacy and role in managing these conditions.